Nektar Therapeutics NKTR Stock Price Today

earnings report
oil & gas

Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach. These stocks include Disney , Casey’s General Stores , OpGen , Accelerate Diagnostics and Nekt… The Zacks Industry Rank assigns a rating to each of the 265 X Industries based on their average Zacks Rank. The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

companies

It is this reason that could see investor optimism for the NKTR stock continues to rise going into the next quarter. 5 equities research analysts have issued 1 year price targets for Nektar Therapeutics’ stock. Their NKTR share price forecasts range from $1.50 to $3.00.

NKTR Nektar Therapeutics

Advancements in biotech have led to the development of medicines such as mRNA therapeutics. Yet, the complex science behind these novel biotechnologies can often be difficult for both healthcare providers and consumers to understand. Other market data may be delayed by 15 minutes or more. As an investor, you want to buy stocks with the highest probability of success.

Consensus Price Target is the stock price analysts expect to see within a period of 0-18 months. Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view.

Lead Independent Director exercised options to buy US$654k worth of stock.

CompareNKTR’s historical performanceagainst its industry peers and the overall market. Moats and returns on invested capital look stable for companies with a solid list of pipeline drugs. Nektar reports encouraging third-quarter 2022 results. The narrower-than-expected loss is on account of lower operating expenses incurred during the quarter. Shares of Nektar Therapeutics NKTR, -1.66% plunged more than 30% in the extended session Thursday after the biopharma company reported that a study did not meet goals and that partner Eli Lilly & Co. …

Why Nektar Therapeutics Stock Is Plunging Today – Yahoo Finance

Why Nektar Therapeutics Stock Is Plunging Today.

Posted: Fri, 24 Feb 2023 08:00:00 GMT [source]

Comparatively, Rogers Corpocommand publishn has moved 0.69% on the day and only -42.90% in the past 12 months. Moreover, Eli Lilly and Company is also up 3.74% in trading on the day while keeping a an uptrend of 38.02% over the past year. Elsewhere, the overall performance for the S&P 500 and Dow Jones Industrial shows that the indexes are up 1.96% and 1.57% respectively in the last trading. Analysts have a consensus estimate of $16.92 million for the company’s revenue for the quarter, with a low and high estimate of $8.86 million and $20.14 million respectively.

Price History & Performance

Real-time quotes, advanced visualizations, backtesting, and much more. Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.

  • Lead Independent Director exercised options to buy US$654k worth of stock.
  • The Price-to-Earnings (or P/E) ratio is a commonly used tool for valuing a company.
  • This, combined with strong agreement among Wall Street analysts in revising ea…

On average, they anticipate the company’s share price to reach $2.50 in the next year. This suggests a possible upside of 229.6% from the stock’s current price. View analysts price targets for NKTR or view top-rated stocks among Wall Street analysts. The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock.

Nektar Therapeutics(NasdaqGS:NKTR) dropped from Russell 1000 Dynamic Index

Investing.com – U.S. equities were higher at the close on Friday, as gains in the Telecoms, Utilities and Technology sectors propelled shares higher. Investing.com – U.S. equities were higher at the close on Monday, as gains in the Basic Materials, Technology and Consumer Goods sectors propelled shares higher. Investing.com – U.S. equities were higher at the close on Wednesday, as gains in the Oil & Gas, Technology and Consumer Services sectors propelled shares higher. Investing.com – U.S. equities were higher at the close on Monday, as gains in the Utilities, Telecoms and Technology sectors propelled shares higher. Investing.com – U.S. equities were lower at the close on Monday, as losses in the Utilities, Oil & Gas and Financials sectors propelled shares lower. Investing.com – U.S. equities were higher at the close on Thursday, as gains in the Consumer Goods, Basic Materials and Healthcare sectors propelled shares higher.

zacks rank #

Specifically, they have bought $0.00 in company stock and sold $121,158.00 in company stock. 4.34% of the outstanding shares of Nektar Therapeutics have been sold short. MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation. News Corp is a global, diversified media and information services company focused on creating and distributing authoritative and engaging content and other products and services. EBITDA is a widely used measure of corporate profitability. It stands for Earnings before Interest, Taxes, Depreciation, and Amortization.

Investing.com – U.S. equities were lower at the close on Friday, as losses in the Oil & Gas, Consumer Goods and Basic Materials sectors propelled shares lower. Investing.com – U.S. equities were higher at the close on Friday, as gains in the Technology, Consumer Goods and Oil & Gas sectors propelled shares higher. Investing.com – U.S. equities were higher at the close on Thursday, as gains in the Healthcare, Technology and Consumer Services sectors propelled shares higher. Investing.com – U.S. equities were higher at the close on Friday, as gains in the Oil & Gas, Consumer Services and Basic Materials sectors propelled shares higher. Investing.com – U.S. equities were lower at the close on Tuesday, as losses in the Telecoms, Utilities and Basic Materials sectors propelled shares lower. Investing.com – U.S. equities were higher at the close on Monday, as gains in the Consumer Services, Utilities and Basic Materials sectors propelled shares higher.

Investing.com – U.S. equities were higher at the close on Tuesday, as gains in the Technology, Industrials and Financials sectors propelled shares higher. Investing.com – U.S. equities were higher at the close on Wednesday, as gains in the Utilities, Technology and Industrials sectors propelled shares higher. Investing.com – U.S. equities were mixed at the close on Monday, as gains in the Technology, Consumer Services and Consumer Goods sectors propelled shares higher while losses in the… Investing.com – U.S. equities were mixed at the close on Thursday, as gains in the Consumer Services, Technology and Healthcare sectors propelled shares higher while losses in the Telecoms,… Investing.com – U.S. equities were mixed at the close on Monday, as gains in the Financials, Healthcare and Utilities sectors propelled shares higher while losses in the Oil & Gas,… Dividend yield allows investors, particularly those interested in dividend-paying stocks, to compare the relationship between a stock’s price and how it rewards stockholders through dividends.

In the Morningstar Style Box, large-cap names account for the largest 70% of U.S. stocks, mid-cap names account for the largest 70–90%, and small-cap names are the remaining 10% of companies. Nektar Therapeutics is a research-based biopharmaceutical company which engages in discovering and developing medicines in areas of unmet medical need. Its research and development pipeline of new investigational drugs includes therapies for oncology, immunology and virology. The firm focuses on using new chemistry approaches to make medicines to treat cancer and autoimmune diseases. The company was founded in 1990 and is headquartered in San Francisco, CA.

The up/down ratio is calculated by dividing the value of uptick trades by the value of downtick trades. Net money flow is the value of uptick trades minus the value of downtick trades. Our calculations are based on comprehensive, delayed quotes. The Price-to-Earnings (or P/E) ratio is a commonly used tool for valuing a company. It’s calculated by dividing the current share price by the earnings per share .

  • It attempts to reflect the cash profit generated by a company’s operations.
  • ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating indiv idual securities.
  • Elsewhere, the overall performance for the S&P 500 and Dow Jones Industrial shows that the indexes are up 1.96% and 1.57% respectively in the last trading.
  • This news sentiment score is similar to the average news sentiment of Medical companies.
  • Nektar Therapeutics has received a 60.23% net impact score from Upright.

Zacks Earnings ESP looks to find companies that have recently seen positive earnings estimate revision activity. The idea is that more recent information is, generally speaking, more accurate and can be a better predictor of the future, which can give investors an advantage in earnings season. You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating indiv idual securities. Nektar Therapeutics has a short interest ratio (“days to cover”) of 1.7, which is generally considered an acceptable ratio of short interest to trading volume.

There may be delays, omissions, or inaccuracies in the Information. The https://1investing.in/ with the best average Zacks Rank would be considered the top industry , which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank would place in the bottom 1%. An industry with a larger percentage of Zacks Rank #1’s and #2’s will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4’s and #5’s.

The average forecast suggests down to a -31.80% growth in sales growth compared to quarterly growth in the same period last fiscal year. Wall Street analysts have also projected the company’s year-on-year revenue for 2023 to grow to $67.95 million, representing a -8.40% decline on that reported in the last financial year. Nektar Therapeutics has a news sentiment score of 0.65. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 to -2 .

7 Sorry Pharma Stocks to Sell in April Before It’s Too Late – InvestorPlace

7 Sorry Pharma Stocks to Sell in April Before It’s Too Late.

Posted: Sat, 15 Apr 2023 07:00:00 GMT [source]

According to analysts’ consensus price target of $2.50, Nektar Therapeutics has a forecasted upside of 226.0% from its current price of $0.77. Dow Jones Industrial Average, S&P 500, Nasdaq, and Morningstar Index quotes are real-time. This Gold-rated large-cap fund’s multimanager approach has richly rewarded investors. Coaxing cells to produce mRNA for therapeutic applications has been an unsuccessful endeavor so far. Miroslav Gasparek is on a mission to use synbio to change that. His company Sensible Biotechnologies is partnering with Ginkgo Bioworks to develop the next generation of mRNA therapeutics.

This is an increase of 346% compared to the previous 30 days. Nektar Therapeutics has received a 60.23% net impact score from Upright. Short interest in Nektar Therapeutics has recently decreased by 3.53%, indicating that investor sentiment is improving.

rated

This news sentiment score is similar to the average news sentiment of Medical companies. Shares Sold ShortThe total number of shares of a security that have been sold short and not yet repurchased.Change from LastPercentage change in short interest from the previous report to the most recent report. Exchanges report short interest twice a month.Percent of FloatTotal short positions relative to the number of shares available to trade. Investing.com – U.S. equities were mixed at the close on Wednesday, as gains in the Basic Materials, Industrials and Utilities sectors propelled shares higher while losses in the Healthcare,… Last month we talked about how Nektar Therapeutics stock seems to be a good buying opportunity, and now there have been more positive developments for the company.

Independent Director exercised options to buy US$701k worth of stock. Independent Director exercised options to buy US$714k worth of stock. Lead Independent Director exercised options to buy US$654k worth of stock. Independent Director exercised options to buy US$169k worth of stock. Join thousands of traders who make more informed decisions with our premium features.

Leave a Reply

Your email address will not be published. Required fields are marked *

Compare

Open chat
1
Need Help?
Hello 👋
Can we help you?